GlassScriptPhysician profile
Rahul K Patel
NPI 1548311319
$8,945.16
in general payments reported to CMS, 2019-2025
25 companies · $687 in 2025
The $687 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $256 · 2021: $5,692 · 2022: $872 · 2023: $434 · 2024: $693 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,813.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $5,156.11 | 2021 | |
| Abbvie INC. | $513.83 | 2022-2025 | |
| Alcon Vision LLC | $461.03 | 2021-2025 | Rocklatan, Clareon Panoptix Pro, Clareon |
| Tarsus Pharmaceuticals, INC. | $311.33 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $310.09 | 2021-2024 | Acthar |
| Novartis Pharmaceuticals Corporation | $291.54 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $247.40 | 2019-2023 | Cequa |
| Dompe US, INC. | $235.17 | 2020-2025 | Oxervate |
| Allergan, INC. | $203.38 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $178.57 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Oyster Point Pharma, INC. | $177.39 | 2022-2024 | Tyrvaya, Ryzumvi |
| Kala Pharmaceuticals, INC. | $146.82 | 2020-2021 | |
| Ocular Therapeutix, INC. | $139.44 | 2019-2025 | Dextenza |
| Biotissue Holdings INC. | $94.81 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $82.96 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $67.39 | 2023-2024 | Lipiflow System Activator II (Disposable, Tecnis Iol |
| Medtronic, INC. | $66.86 | 2025 | Straightshot |
| Amgen INC. | $56.62 | 2025 | Tepezza |
| Thea Pharma INC. | $46.56 | 2023-2024 | Iyuzeh |
| Rayner Intraocular Lenses Limited | $40.77 | 2023-2024 | Rayone Emv, Rayone Aspheric, Omidria |
| Omeros Corporation | $33.92 | 2019 | |
| Eyevance Pharmaceuticals LLC | $31.74 | 2019-2022 | |
| Astellas Pharma US INC | $23.32 | 2025 | Izervay |
| Eyepoint US, INC. | $14.30 | 2019 | |
| Shire North American Group INC | $13.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.